Valsartan
Average across 38 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Camber Pharmaceuticals, Inc. | unknown | 40 | SUPPLYING |
| Dr.Reddy's laboratories Limited | unknown | 22 | SUPPLYING |
| Bryant Ranch Prepack | repackager | 18 | SUPPLYING |
| Laurus Labs Limited | unknown | 15 | SUPPLYING |
| Unichem Pharmaceuticals (USA), Inc. | unknown | 12 | SUPPLYING |
| OHM LABORATORIES INC | unknown | 12 | SUPPLYING |
| Ascend Laboratories, LLC | unknown | 12 | SUPPLYING |
| A-S Medication Solutions | unknown | 8 | SUPPLYING |
| Aurobindo Pharma Limited | unknown | 8 | SUPPLYING |
| Macleods Pharmaceuticals Limited | unknown | 8 | SUPPLYING |
| Northwind Health Company, LLC | unknown | 5 | SUPPLYING |
| Proficient Rx LP | unknown | 5 | SUPPLYING |
| Zydus Lifesciences Limited | unknown | 4 | SUPPLYING |
| AvPAK | unknown | 4 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | unknown | 4 | SUPPLYING |
+ 5 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
Valsartan Tablet — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Cardiovascular.
Valsartan Tablet — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Cardiovascular.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Hetero Labs Limited Unit V — Nationwide
Pill